Opendata, web and dolomites

InflammaTENSION SIGNED

A study of the roles of the immune and inflammatory systems in hypertension.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "InflammaTENSION" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF GLASGOW 

Organization address
address: UNIVERSITY AVENUE
city: GLASGOW
postcode: G12 8QQ
website: www.gla.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 1˙957˙573 €
 EC max contribution 1˙957˙573 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-COG
 Funding Scheme ERC-COG
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF GLASGOW UK (GLASGOW) coordinator 1˙957˙573.00

Map

 Project objective

Hypertension is a common disease impacting 1 billion people worldwide, which leads to catastrophic cardiovascular complications. The cause of primary hypertension is unknown and the disease remains uncontrolled in many patients. By interrogating the key hypothesis that inflammatory dysregulation fundamentally controls development of hypertension and vascular remodelling, InflammaTENSION provides a new paradigm for the management of the disease, with the potential to lead to identification of novel therapeutic targets to control hypertension. InflammaTENSION will result in the discovery of novel biomarkers, capable of identifying patients who could benefit from such immune targeted therapies. Importantly, we already made the seminal observation that the immune system not only mediates target organ damage, but is essential for the development of hypertension. This finding has initiated numerous studies, that defined the roles of pro-inflammatory T cells, monocytes and anti-inflammatory T regulatory cells. However, our current knowledge remains very fragmented and so far has not been applied to human pathology. InflammaTENSION will for the first time advance the knowledge procured in rodent models into human studies. By combining clinical translational and model mechanistic studies it will identify novel inflammatory factors that can control immune mechanisms of hypertension. We will: (1) characterize the immunophenotypic signature of human hypertension; (2) define key concepts in cytokine biology of hypertension with TNF-α and IL-6 as key exemplars; (3) understand how chronic cytokines regulate the T cell dependent mechanisms of hypertension. InflammaTENSION will go beyond current state-of-the-art through comprehensive combination of immunology and cardiovascular medicine to create a new understanding of how the immune system may lead to human hypertension and will have major impact on the field, enabling translation of these exciting findings to clinical practice.

 Publications

year authors and title journal last update
List of publications.
2017 Tomasz J Guzik
Heterogenous treatment effects: secrets for a reliable treat-to-target trial?
published pages: e18-e20, ISSN: 0008-6363, DOI: 10.1093/cvr/cvx081
Cardiovascular Research 113/7 2019-05-15
2019 Pasquale Maffia, Tomasz J Guzik
When, where, and how to target vascular inflammation in the post-CANTOS era?
published pages: , ISSN: 0195-668X, DOI: 10.1093/eurheartj/ehz133
European Heart Journal 2019-05-15
2018 Pawel Maga, Tomasz P. Mikolajczyk, Lukasz Partyka, Mateusz Siedlinski, Mikolaj Maga, Marek Krzanowski, Krzysztof Malinowski, Kevin Luc, Rafal Nizankowski, Deepak L. Bhatt, Tomasz J. Guzik
Involvement of CD8+ T cell subsets in early response to vascular injury in patients with peripheral artery disease in vivo
published pages: 26-33, ISSN: 1521-6616, DOI: 10.1016/j.clim.2018.06.006
Clinical Immunology 194 2019-05-15
2018 Tomasz J. Guzik, Francesco Cosentino
Epigenetics and Immunometabolism in Diabetes and Aging
published pages: 257-274, ISSN: 1523-0864, DOI: 10.1089/ars.2017.7299
Antioxidants & Redox Signaling 29/3 2019-05-15
2018 Marta Czesnikiewicz-Guzik, Ryszard Nosalski, Tomasz P Mikolajczyk, Francesca Vidler, Tomasz Dohnal, Elzbieta Dembowska, Delyth Graham, David G Harrison, Tomasz J Guzik
Th1-type immune responses to Porphyromonas gingivalis antigens exacerbate angiotensin II-dependent hypertension and vascular dysfunction
published pages: , ISSN: 0007-1188, DOI: 10.1111/bph.14536
British Journal of Pharmacology 2019-05-15
2019 Tomasz P. Mikolajczyk, Ryszard Nosalski, Dominik S. Skiba, Joanna Koziol, Magdalena Mazur, Amauri S. Justo‐Junior, Paulina Kowalczyk, Zofia Kusmierczyk, Agata Schramm‐Luc, Kevin Luc, Pasquale Maffia, Delyth Graham, Anna K. Kiss, Marek Naruszewicz, Tomasz J. Guzik
1,2,3,4,6‐Penta‐ O ‐galloyl‐β‐ d ‐glucose modulates perivascular inflammation and prevents vascular dysfunction in angiotensin II‐induced hypertension
published pages: , ISSN: 0007-1188, DOI: 10.1111/bph.14583
British Journal of Pharmacology 2019 Jan 18 2019-05-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INFLAMMATENSION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INFLAMMATENSION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

TransTempoFold (2019)

A need for speed: mechanisms to coordinate protein synthesis and folding in metazoans

Read More  

MATCH (2020)

Discovering a novel allergen immunotherapy in house dust mite allergy tolerance research

Read More